SuperworthNeogenomics shares outstanding NEO
Diluted shares outstanding, averaged over each quarter, from 2011.
- Latest quarter, to Jun 30, 2026
- 130.8M
- On a year earlier
- +2.3%
- more shares
Neogenomics had 130.8M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 2.3% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 128.6M | +1% |
| FY2024 | 127.2M | +1% |
| FY2023 | 125.9M | +1% |
| FY2022 | 124.7M | +2% |
| FY2021 | 122.6M | +7% |
| FY2020 | 114.7M | +6% |
| FY2019 | 107.8M | +11% |
| FY2018 | 96.9M | +9% |
| FY2017 | 88.6M | +13% |
| FY2016 | 78.5M | +29% |
| FY2015 | 60.9M | −2% |
| FY2014 | 62.2M | +16% |
| FY2013 | 53.6M | +18% |
| FY2012 | 45.3M | +0% |
| FY2011 | 45.3M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 130.8M | +2% | |
| Q1 FY26 | 129.2M | +1% | |
| Q4 FY25 | 128.6M | +1% | |
| Q3 FY25 | 128.4M | +1% | |
| Q2 FY25 | 127.9M | +1% | |
| Q1 FY25 | 127.4M | +1% | |
| Q4 FY24 | 127.2M | +1% | |
| Q3 FY24 | 127M | +1% | |
| Q2 FY24 | 126.4M | +1% | |
| Q1 FY24 | 126.1M | +1% | |
| Q4 FY23 | 125.9M | +1% | |
| Q3 FY23 | 125.7M | +1% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Neogenomics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.